FDA rejects TOOKAD focal treatment fo... - Prostate Cancer N...

Prostate Cancer Network

5,254 members3,320 posts

FDA rejects TOOKAD focal treatment for low-risk prostate cancer

Tall_Allen profile image
8 Replies

I updated this article to reflect the rejection this week of a kind of photodynamic therapy for low-risk prostate cancer. It was a good call, IMO.

pcnrv.blogspot.com/2017/01/...

Those interested in any focal ablative therapy (e.g., HIFU, cryo, FLA, etc.) should read this first:

pcnrv.blogspot.com/2016/12/...

Written by
Tall_Allen profile image
Tall_Allen
To view profiles and participate in discussions please or .
Read more about...
8 Replies

Thanks TA for the post. I think it makes sense.

Gemlin_ profile image
Gemlin_

Must have been expected. Is there any focal therapy recommended for clinical practice in US? Not so in Europe.

Tall_Allen profile image
Tall_Allen in reply toGemlin_

The FDA would not approve HIFU for the treatment of prostate cancer. The HIFU manufacturers said, "if you won't approve our machines for the treatment of prostate cancer, will you at least approve it for the removal of prostate tissue?" So once the FDA approved it for that purpose, they couldn't stop urologists from using it in men who had prostate cancer. Insurance won't cover it, however. So Uros charge patients about $20,000 out-of-pocket per treatment, and it usually involves multiple treatments.

Cryo sometimes gets covered because there is a registry.

in reply toTall_Allen

Cigna now covers HIFU.

Philip_Craig profile image
Philip_Craig

Thanks for posting. I was one of the 50 at MSK that had this twice, both times they did not get it all.

Adf2529 profile image
Adf2529

Interesting. Thanks for posting.

tallguy86 profile image
tallguy86

Always grateful to you for posting articles and research outcomes and other issues related to Pca. Be well!

garyi profile image
garyi

Thanks....facts are always better than rumors.

Not what you're looking for?

You may also like...

Should SBRT be THE preferred treatment for intermediate risk prostate cancer?

Unfortunately, not enough patients meet with a radiation oncologist who specializes in SBRT. While...
Tall_Allen profile image

FDA approves Erleada for metastatic hormone-sensitive prostate cancer

Joining Zytiga, and docetaxel. Probably Xtandi too very soon....
Tall_Allen profile image

Long-term adjuvant ADT improves results of brachy boost therapy in unfavorable-risk prostate cancer patients

For most unfavorable risk prostate cancer patients, brachy boost therapy is the preferred option....
Tall_Allen profile image

What treatment for recurrent prostate cancer?

I'm new here. At a general health check end 2010, a PSA of 28 was detected. After MRI, CT scan and...
PCPatient profile image

More proof that results of SBRT are equivalent to IMRT (yet faster and cheaper)

I am pleased that SBRT was my choice of primary therapy 8 years ago. The randomized comparisons are...
Tall_Allen profile image

Moderation team

Bethishere profile image
BethishereAdministrator
Number6 profile image
Number6Administrator
Darryl profile image
DarrylPartner

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.